$599 Million is the total value of RTW INVESTMENTS, LP's 32 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | Buy | PTC Therapeutics Inc | $68,890,000 | -1.5% | 4,130,115 | +18.2% | 11.50% | -5.6% |
| RGNX | Buy | Regenxbio Inc | $51,910,000 | +2.4% | 1,561,210 | +1.4% | 8.66% | -1.9% |
| BMY | Buy | Bristol-Myers Squibb Co | $51,442,000 | -2.5% | 839,452 | +1.4% | 8.59% | -6.5% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $45,582,000 | -37.8% | 358,774 | -42.4% | 7.61% | -40.4% |
| DRNA | Buy | Dicerna Pharmaceuticals Inc | $44,142,000 | +269.3% | 5,035,662 | +142.2% | 7.37% | +253.9% |
| ACHN | Buy | Achillion Pharmaceuticals Inc | $39,015,000 | +10.8% | 13,546,902 | +72.8% | 6.51% | +6.2% |
| LJPC | Buy | La Jolla Pharmaceutical Co | $34,213,000 | -5.8% | 1,063,170 | +1.8% | 5.71% | -9.7% |
| AVXS | Sell | Avexis Inc | $31,125,000 | -31.2% | 281,242 | -39.9% | 5.20% | -34.1% |
| ABUS | Sell | Arbutus Biopharma Corp | $26,016,000 | -20.3% | 5,151,615 | -2.2% | 4.34% | -23.6% |
| GBT | Buy | Global Blood Therapeutics Inc | $23,676,000 | +2797.9% | 601,683 | +2186.9% | 3.95% | +2683.1% |
| OSUR | Buy | OraSure Technologies Inc | $16,568,000 | +37.5% | 878,452 | +64.0% | 2.76% | +31.7% |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $16,560,000 | -4.9% | 3,372,674 | +1.4% | 2.76% | -8.9% |
| CORI | Buy | Corium International Inc | $16,334,000 | -12.0% | 1,699,653 | +1.4% | 2.73% | -15.7% |
| AGEN | Buy | Agenus Inc | $14,115,000 | -24.1% | 4,329,816 | +2.6% | 2.36% | -27.3% |
| EW | New | Edwards Lifesciences Corp | $13,863,000 | – | 123,000 | +100.0% | 2.31% | – |
| VRAY | Buy | Viewray Inc | $12,484,000 | +112.4% | 1,348,210 | +32.1% | 2.08% | +103.5% |
| MYOK | Buy | Myokardia Inc | $10,848,000 | -0.3% | 257,663 | +1.5% | 1.81% | -4.4% |
| MASI | Masimo Corp | $10,252,000 | -2.0% | 120,900 | 0.0% | 1.71% | -6.1% | |
| ATRA | Sell | Atara Biotherapeutics Inc | $10,066,000 | -7.3% | 556,118 | -15.2% | 1.68% | -11.2% |
| PTI | New | Proteostasis Therapeutics Inc | $8,745,000 | – | 1,500,000 | +100.0% | 1.46% | – |
| VIVE | Buy | Viveve Medical Inc | $8,315,000 | +7.7% | 1,672,998 | +13.6% | 1.39% | +3.3% |
| QURE | New | Uniqure NV | $7,905,000 | – | 403,524 | +100.0% | 1.32% | – |
| VCEL | New | Vericel Corp | $7,111,000 | – | 1,304,801 | +100.0% | 1.19% | – |
| ODT | New | Odonate Therapeutics Inc | $6,768,000 | – | 297,555 | +100.0% | 1.13% | – |
| TCMD | Sell | Tactile Systems Technology Inc | $6,096,000 | -44.2% | 210,366 | -40.4% | 1.02% | -46.5% |
| OXFD | Sell | Oxford Immunotec Global PLC | $5,250,000 | -69.7% | 375,792 | -63.6% | 0.88% | -71.0% |
| BVX | Buy | Bovie Medical Corp | $4,557,000 | +18.3% | 1,752,611 | +53.8% | 0.76% | +13.4% |
| ZYNE | Buy | Zynerba Pharmaceuticals Inc | $2,540,000 | +51.9% | 202,859 | +1.4% | 0.42% | +45.7% |
| FPRX | New | Five Prime Therapeutics Inc | $2,200,000 | – | 100,377 | +100.0% | 0.37% | – |
| ARGX | Buy | argenx NVsponsored adr | $1,595,000 | +183.3% | 25,260 | +1.4% | 0.27% | +171.4% |
| RVNC | New | Revance Therapeutics Inc | $824,000 | – | 23,038 | +100.0% | 0.14% | – |
| SRTSW | Sell | SENSUS HEATLHCARE INC*w exp 06/08/201 | $98,000 | +8.9% | 151,400 | -2.3% | 0.02% | 0.0% |
| SBPH | Exit | Spring Bk Pharmaceuticals In | $0 | – | -249,095 | -100.0% | -0.73% | – |
| BLUE | Exit | bluebird bio Inc | $0 | – | -104,078 | -100.0% | -2.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-02-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.